related documents
- Benefits of candesartan are consistent regardless of pre-treatment systolic blood pressure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. Conferences
- Black patients with symptomatic heart failure have similar outcomes and response to angiotensin receptor blockade as white patients Conferences
- Candesartan benefits and safety observed regardless of age. Insights from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. Conferences
- Comparison of the risk associated with diabetes mellitus in patients with preserved and low ejection fraction heart failure: An analysis of the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program Conferences
- Efficacy and safety of fonclaparinux in elderly patients with ST segment elevation myocardial infarction: Data from the OASIS 6 trial Conferences
- Impaired therapeutic potential of bone marrow-derived endothelial progenitor cells in the metabolic syndrome and diabetes mellitus. Conferences
- Liver function test abnormalities and outcome in patients with chronic heart failure: Data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program Conferences
- Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome Conferences
- N-terminal pro BNP is associated with cardiac structure and function in elderly patients with heart failure and preserved systolic function; the iPRESERVE study Conferences
- Red cell distribution width as a novel prognostic marker in heart failure: Data from the CHARM program and the duke databank Conferences
- The effect of valsartan compared to valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: The Val-MARC trial Conferences